{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 25,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide demonstrates superior tumor growth inhibition by NXP800 compared to Cisplatin in both resistant and sensitive models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/9",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.31,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "chart",
      "text": "SKOV-3 (Cisplatin Resistant) tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f9b1697-7a66-4dcf-bb3e-2cdbe30a016d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.31,
        "x": 0.34,
        "y": 0.3
      },
      "kind": "chart",
      "text": "TOV-21G (Cisplatin Sensitive) tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8edf937-22d1-4d93-9558-85bdf799f192",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.67,
        "y": 0.68
      },
      "kind": "source-note",
      "text": "a. Based on data from the American Cancer Society, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e08affb-a279-489a-8403-a64f0650df19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.3
      },
      "kind": "table",
      "text": "Disease incidence and ARID1a deficiency patient estimates",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cadd5ba0-f5a0-4db1-9d4f-f202ad7b0c2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "title",
      "text": "Preclinical proof of concept leading to selection of initial target indications",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f4dc9db-9cca-42e4-9111-292d129e4859",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts (NXP800 vs. Cisplatin)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bd7f5e0-8346-4e14-bd7b-f3cea98e6a01",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 4,
      "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
      "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
      "position": 0,
      "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}